As a payer, Brian B. Kiss, MD, vice president, healthcare transformation, Blue Cross Blue Shield of Florida, acknowledges that benefit design is complex and the benefit structure for end-of-life care can be funded differently. “We’re working on the system to make these decisions,” he says. Plan designs are shifting toward out-of-pocket maximums; a patient receiving chemotherapy treatment will almost certainly reach that maximum cost-sharing limit, and possibly after only 1 month of therapy.
“The benefit design is a nightmare,” states Bruce A. Feinberg, DO, vice president and chief medical officer of Cardinal Health Specialty Solutions. Frequently, benefit design does not take the personalized aspect of medicine into account, which is so important in palliative care. It is important that benefit design alleviates the problem, he adds.
Dr Kiss believes that we need benefit designs that will not hinder patients from taking oral oncolytics or filling a prescription. It is important to have a value-based benefit design that motivates patients to do the right thing for themselves, notes Dr Kiss, and this is even more critical in palliative care. There should be as little obstruction as possible for patients to fill that prescription or take that full prescribed dose.
As payers we need to address some of those structural issues and that may mean “looking at changing and moving to value-based benefit design,” says Dr Kiss.
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Risk for Second Primary Melanoma Increases After Primary Melanoma Diagnosis as Men Age
March 28th 2024A population-based cohort study out of Norway has found that older men have a higher risk of developing second primary invasive melanoma following an initial primary melanoma, suggesting the benefits of increased surveillance in these patients.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
CMS released a final rule to help patients obtain Children’s Health Insurance Program (CHIP) coverage and issued a proposed rule to update Medicare payment policies and rates for inpatient rehabilitation facilities; debate over if gift card incentives are acceptable in health care marketing.
Read More